Question
Asked 2nd Mar, 2017

Can community/population carriage of resistant bacteria predict the incidence of invasive disease by resistant bacteria?

There is evidence for emergence of resistance in carried bacteria following antibiotic use in primary, secondary and tertiary care settings. And for example, the pneumococcal conjugate vaccine reduces the prevalence of resistant pneumococci in carriage.
Can community/population carriage of resistant bacteria predict the incidence of invasive disease by resistant bacteria?

Most recent answer

I agree. I think this is can be demonstrated when studying PCV herd effects; lowering resistant IPD suggests that carriage of resistant serotypes predicts disease in the population. 

All Answers (4)

Any takers, I would really appreciate your insights/feedback. Thanks
Interesting question, Ifedayo. In pneumococcal disease, there is a measure that reflects carriage-disease relationship, called "invasiveness ratio". You may read the study by Weinberger et al (AJE 2016), where they showed that carriage/invasiveness data in children can predict invasive disease in adults. The implications extend to forecasting the impact of new vaccines. I am not aware of similar studies specifically designed to assess resistant serotypes, but I assume they wouldn't behave differently. 
Thank you, Omar Okasha.
I have seen the Weinberger paper because I also have a side interest in modeling changes to invasive pneumococcal disease following vaccine introduction using carriage data. I am not sure this model would directly apply to the incidence of resistant IPD following carriage of resistant pneumococci but it is an interesting question to tackle if the data to do so is available.
I agree. I think this is can be demonstrated when studying PCV herd effects; lowering resistant IPD suggests that carriage of resistant serotypes predicts disease in the population. 

Similar questions and discussions

Opinion on the new trend in antimicrobial stewardship?
Question
4 answers
  • Junel PadigosJunel Padigos
I would like to address this question to doctors, pharmacists, nurses and scientists, especially infectious diseases specialists.
What is your opinion or stand on this editorial by Dr Brad Spellberg published in JAMA on September 2016, The New Antibiotic Mantra—“Shorter Is Better”
On the last paragraph, it was stated: "Here we need to change the dogma: patients should no longer be told to keep taking the antibiotic. Patients should be told that if their symptoms resolve before completing the antibiotic they should communicate with their physician to determine if they can stop the therapy early. Health care professionals should be encouraged to allow patients to stop antibiotic treatment as early as possible on resoultion of symptoms of infection".
I would like to know if this will have any effect on your practice. What do you do to embed this in your practice as a doctor?

Related Publications

Got a technical question?
Get high-quality answers from experts.